rTMS(also referred to simply asTMS) is a non-invasive and medication-free treatment method for people with Depression.rTMS has minimal side-effectsand is more comfortable for patients than ECTas it can be conducted in outpatient settings.
The analysisshowedthat using rTMSas the first option for patients with treatment-resistant Depressionwould saveUSD 46,094per patient over a lifetime compared to ECT.
The authors of the study concluded rTMS as a first line treatment for Depression is more cost effective than ECT long-term, as itslower side effect profile and greater patient acceptability allow it to be administered more times than ECT in a patient’s lifetime.
Whereas previous analyses comparing both methods have been restricted to 6-24 months and have not considered indirect costs,this study simulates both direct and indirect costsalong with the health benefits of patients over their lifetime. In this modelrTMS was also used across all treatment–resistant Depression patients, and patients who did not respond to rTMS were then treated with ECT.
“It’s great to see progressive discussions around the use of rTMS as a first line treatment of depression,” said Dr Trevor Brown, rTMS Trainer & Head Neuroscientist at neurocare Group Austalia,“We see a lot more interest from Psychiatrists wanting to seek professional training in rTMS”.
Therapists at neurocare use an approach which combines rTMS and Psychotherapy, scientificallyproven to be more effective than either therapy alone for people with Depression who have not responded to other therapies.